A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Tennessee's Medicaid program, TennCare, covers drugs like Ozempic and Mounjaro to treat those with diabetes and heart ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

Novo Nordisk has launched Wegovy – its popular weight loss treatment – in China. China, with a population of 1.4 billion, has ...

Kennedy has promised to "Make America Healthy Again" by tackling obesity with nutrition. Here's how he could rattle the ...

Join the debate on weight loss drugs at NAILBA 43. Experts discuss the risk factors and effectiveness of GLP-1 drugs like Ozempic.